Drugs / ABT-384
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01009216 | Oct 2009 → Nov 2010 | — | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00968422 | Aug 2009 → Jan 2010 | — | Abbott | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01137526 | May 2010 → Jul 2011 | Alzheimer disease | AbbVie | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-384 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00968422 ↗ |
| Action | Inhibit | “The selective 11-β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor ABT-384 blocked regeneration of active cortisol” PMID 24418055 ↗ Jan 20141“11-beta-hydroxysteroid dehydrogenase 1 inhibitor” CHEMBL4297256 ↗ |
| Modality | Small molecule | — CHEMBL4297256 ↗ |
| Target | HSD11B1 | “11-beta-hydroxysteroid dehydrogenase 1 inhibitor” CHEMBL4297256 ↗ |